GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Medicago is using GlaxoSmithKline's vaccine adjuvant in its clinical-stage COVID-19 vaccine.

GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact

Philip Morris

GSK , the world's largest vaccine maker, on Tuesday announced the latest partnership for its vaccine booster technology to develop and test a potential COVID-19 shot with Canadian biopharmaceutical firm Medicago.

GSK, Philip Morris venture tie-up for potential COVID-19 shot

A drug manufacturer with a high-yield dividend, but some concerning fundamentals

Is GlaxoSmithKlein’s Dividend Enough to Offset Its Slowing Cash Flow?

GlaxoSmithKline (GSK) closed at $40.55 in the latest trading session, marking a -1.39% move from the prior day.

GlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should Know

Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.

Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine

AstraZeneca

Johnson & Johnson

Moderna

Novavax

Pfizer

Globally, there are more than 100 vaccines under development - with nine of them in human clinical trials already.

Who's Ahead In Finding A COVID-19 Vaccine?

The pharmaceutical giant recently cut its dividend, but it still pays a better yield than most in the industry.

Is GlaxoSmithKline a Great Dividend Stock?

FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.

Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers

Shares of GlaxoSmithKline GSK, +0.52% were down 0.05% in premarket trading on Monday after the Food and Drug Administration late on Friday approved its HIV drug Tivicay as a treatment for infants and children.

GSK gets FDA approval for HIV drug for children

Amgen

BioNTech SE

Gilead Sciences

Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.

Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus

Inovio Pharmaceuticals

Dozens of drugmakers are developing COVID-19 vaccines and gearing up to produce billions of doses each year.

Is a COVID-19 Vaccine Supply Glut on the Way?

Both pharmaceutical giants are developing coronavirus vaccines. Which is a better buy?

Better Coronavirus Stock: Pfizer or GlaxoSmithKline?

Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.

Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners

Glaxo (GSK) set to enhance its manufacturing capacity to make 1 billion doses of its pandemic vaccine adjuvant, which can be used to improve efficacy and scale up of multiple COVID-19 vaccines.

Glaxo Plans to Make 1B Doses of Coronavirus Vaccine Adjuvant

Simply put, adjuvants make vaccines work better; this one could be useful in conjunction with a number of SARS-CoV-2 vaccine candidates.

GlaxoSmithKline Plans to Produce 1 Billion Doses of Its Pandemic Vaccine Adjuvant in 2021

Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

Coronavirus Vaccine Development Gathers Steam: 4 Winners

The test could diagnose individuals in 20 minutes without the need for lab equipment.

GlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 Test

California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, which recently received validation through a peer-reviewed study published in Nature.

Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test

A study showed that cabotegravir works better than the current pre-exposure prophylaxis treatment, but there may be issues with getting it approved.

GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada

Glaxo's (GSK) long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral pills.

Glaxo's Long-Acting HIV Injection Effective Than Daily Pills

A company mostly held by GlaxoSmithKline said it's ending its study early after finding long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP in preventing HIV transmission.

Glaxo-held firm ends HIV study early as injectable shows higher efficacy than daily pill

Glaxosmithkline sees its Relative Strength Rating hit the 80-plus level.
The post GlaxoSmithKline's Relative Strength Rating Flashes Healthy Signs appeared first on Investor's Business Daily.

GlaxoSmithKline's Relative Strength Rating Flashes Healthy Signs

CytoDyn Inc.

Regeneron Pharmaceuticals

Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.

Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners

Kraft Heinz

Microsoft

These payouts are in good shape and there's plenty of reason to be bullish on these stocks.

News for GlaxoSmithKline Stock (GSK)